3 Statins are the most common pharmacologic intervention in hypercholesterolemic patients, and 1 their use is recognized as a key medical advance leading to a 50% decrease in deaths from heart 2 attack or stroke over the past 30 years. The atheroprotective outcomes of statins are largely 3 attributable to the accelerated hepatic clearance of low-density lipoprotein (LDL)-cholesterol from 4 circulation, following the induction of the LDL receptor. However, multiple studies suggest that 5 these drugs exert additional LDL-independent effects. The molecular mechanisms behind these 6 so-called pleiotropic effects of statins, either beneficial or undesired, remain largely unknown. 7 Here we determined the coding transcriptome, miRNome, and RISCome of livers from mice dosed 8 with saline or atorvastatin to define a novel in vivo epitranscriptional regulatory pathway that 9 links statins to hepatic gluconeogenesis, via the SREBP2-miR-183/96/182-TCF7L2 axis. Notably, 10 multiple genome-wide association studies identified TCF7L2 (transcription factor 7 like 2) as a 11 candidate gene for type 2 diabetes, independent of ethnicity. Conclusion: our data reveal an 12 unexpected link between cholesterol and glucose metabolism, provides a mechanistic 13 explanation to the elevated risk of diabetes recently observed in patients taking statins, and 14 identifies the miR-183/96/182 cluster as an attractive pharmacological candidate to modulate non-15 canonical effects of statins. 16 17 18
and uptake of cholesterol. Among the targets of SREBP2, the LDLR is critical in mediating the reduction 23 in plasma LDL-cholesterol which reduces cardiovascular risk in patients taking statins (2). Meta-analyses 24 of epidemiological data and studies in animal models and cells have demonstrated LDL-cholesterol 25 independent effects of statins, both beneficial (improved endothelial function, decreased vascular 26 4 inflammation, reduced thrombogenic response) and undesired (myalgia, liver damage, memory loss) (3). 27 Importantly, statin therapy is modestly, but significantly, associated dose-dependently with increased 28 new-onset diabetes (reviewed in (4, 5)). Indeed, in 2012 the Federal Drug Administration mandated a 29 modification of the safety label of statins to warn of increased HbA1c and/or fasting plasma glucose. This 30 correlation might be the result of prescription bias, i.e. patients who are at increased risk of developing 31 diabetes are also more prone to dyslipidemias and, consequently, are prescribed statins more frequently; 32 however, different laboratories demonstrated decreased pancreatic b-cell insulin secretion (6), peripheral 33 insulin sensitivity (7, 8) , and skeletal muscle mitochondrial function (9, 10) following treatment with statins 34 in vitro and/or in vivo, thus suggesting that statins per se do indeed impact glucose homeostasis. The 35 role of statins on hepatic glucose production, however, has never been examined. 36 MicroRNAs (miRs) are small, noncoding 20-22 nt RNAs that bind to specific, partially 37 complementary sequences in the 3′ untranslated region (UTR) of target mRNAs and recruit them to the 38 RNA-induced silencing complex (RISC) to promote their cleavage and/or translational repression (11) . 39 Over the last two decades, miRNAs have been recognized as key regulators of multiple 40 (patho)physiological processes as their expression can be tissue-, developmental-, and disease-specific 41 (12). In the context of cholesterol metabolism, we and others reported on miR-33a (reviewed in (13)): an 42 intragenic miRNA encoded within intron 16 of SREBP2 that fine-tunes the expression of several 43 transmembrane sterol transporters involved in high-density lipoprotein (HDL) lipidation (14-17), bile 44 metabolism (18), and hepatic vesicular secretion (19). Since SREBP2 transactivates its own promoter, Animal studies. C57BL/6 mice were obtained from NCI, housed in Optimice racks (Animal Care 54 Systems), maintained on a 12h/12h light/dark cycle with unlimited access to food (PicoLab 5353) and 55 water, and bred in the SPF animal facility at Saint Louis University. All mice used for in vivo experiments 56 were male at 10-12 weeks of age. Animals used for isolation of primary hepatocytes were male or 57 female. Where indicated, mice were gavaged 100 L saline or 10 mg/kg atorvastatin (Cayman 58 Chemicals) once a day for ten days, and on the day of sacrifice once at 8 am and fasted for 6 h prior to 59 tissue collection. For overexpression experiments, animals were infused via tail vein with empty or miR-60 183/96/182 adenoviral vectors (2x10 9 pfu); pyruvate challenges and tissue collection were done 10-and 61 12-days post-infusion, respectively. For antisense experiments, animals were gavaged daily with saline 62 or 10 mg/Kg atorvastatin as above for 6 weeks, then kept on drug while injected i.p. on days 1, 2, 3, 9, 63 and 12 with 100 L saline, scrambled, anti-miR-96, anti-miR-182, or anti-miR-183 oligonucleotides (5 64 mg/kg) or combined anti-miR-96, -182, and -183 oligonucleotides (1.7 mg/Kg each). Pyruvate challenges 65 were done on day 15 at 5 am after removing food at 6 pm the day before. Mice in the antisense 66 experiments were not fasted before collection of blood and livers. For pyruvate challenges, baseline 67 blood glucose was taken from tail snipping using a glucometer (Bayer Contour), then mice were injected 68 i.p. with 2 g/kg pyruvate, as described (21), and sequential glucose measurements were taken 15, 30, 69 and 60 min after pyruvate injection. All animals received humane care according to the criteria outlined in RNA analysis. RNA was extracted from mouse livers and cells using Trizol (Invitrogen). RISC-105 associated RNA was immunoprecipitated from liver homogenates using an anti-AGO2 antibody (Wako, 106 clone 2D4) and extracted as described (24). Bar-coded libraries for small and polyA-enriched large 107 RNAs, and for RISC-associated RNAs were prepared for livers from saline (n=8) and atorvastatin (n=8) 108 treated mice using Illumina kits, and transcriptional profiling by deep sequencing were analyzed as 
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In an effort to understand the functional changes in the hepatic transcriptome that follow 132 treatment with statins, we dosed C57BL/6 mice with saline or atorvastatin, and use RNA-seq to define 133 total mRNAs (coding transcriptome), mRNAs associated with the RISC (RISCome), and miRNAs 134 (miRNome) (Fig. 1a ). The complete annotated sequencing data are available in Supplementary Files 1- goal, however, was to identify transcripts that were both reciprocally regulated in total transcriptome vs. 142 RISCome, and predicted as targets of miRNAs differentially regulated in the miRNome. Analysis of the 143 three sets of data revealed several miR/mRNA pairs that fit those criteria ( Fig. 1e and Supplemental Data 144 Fig. 1 ). In the rest of this report, we focus on the miR-183/96/182 polycistronic cluster, because all 3 145 miRNAs were upregulated in the livers of mice treated with atorvastatin, compared to saline (Fig. 1c ), 146 and 9 predicted targets for one or more miRNAs in that cluster were both RISC-enriched and 147 transcriptome-depleted in the same livers (Fig. 1e ). These targets are Bicd2 (bicaudal D homolog 2), mice, and the fold-induction following treatment with saline. We also highlight miR-33 in the same panels, 153 as we and others have previously described this miRNA as regulated by statins. Data in Fig. 2c show the 154 transcriptome and RISCome scores for the nine potential targets defined above. Importantly, both the 155 induction of the miR cluster and the repression of the nine putative targets in response to statins were 156 9 validated by RT-qPCR in a second cohort of mice (data not shown) and in mouse primary hepatocytes 157 ( Fig. 2d ). Collectively, data in Figs. 1 and 2 demonstrate that miR-183/96/182 is an in vivo hepatic sensor 158 of exposure to statins, and that these miRNAs actively recruit specific mRNA targets to the RISC in 159 response to statins. 160 In agreement with a report by Jeon et al. (20) , we mapped two SREBP-responsive elements 161 (SRE) upstream of the transcription start for the miR-183/96/182 cluster (Supplemental Data Fig. 2a ). 162 The proximal element is evolutionarily conserved between mice and humans, while the distal one is 163 divergent (Supplemental Data Fig. 2b ). Nevertheless, both sequences in the human and mouse 164 promoters confer responsiveness to SREBP2 (Supplemental Data Fig. 2c, d) . 165 Of the nine transcripts that originally fit our criteria ( Figs. 1e and 2c) , we decided to focus on 166 Tcf7l2, as it has been identified as a key transcriptional regulator of hepatic gluconeogenesis, and 167 polymorphisms in this locus have been associated with diabetes in several GWAS (27-31). We 168 hypothesized that statins stimulate hyperglycemia, at least in some patients, by increasing hepatic 169 glucose output via miR-183/96/182-TCF7L2. The miRNA target prediction algorithm Targetscan (32) 170 identifies conserved sequences in the 3' UTR of TCF7L2 that are partially complementary to miR-183, -171 96, -or 182 (Fig. 3a) . These sequences, or the entire 3' UTR of mouse or human TCF7L2, were cloned 172 downstream of a luciferase reporter and transiently transfected into HEK293 cells in the presence or 173 absence of a plasmid encoding each miR. Data from these experiments in Fig. 3b show that each 174 isolated conserved sequence (but not sequence 1 in human TCF7L2, which is not conserved in mouse), 175 as well as the whole 3' UTR, were able to confer responsiveness to miR-183, -96, and -182. Additionally, 176 point mutations in each predicted sequence to prevent interaction with the seed sequence of each 177 miRNA abrogated the response (Supplemental Data Fig. 3 ). Importantly, data in Fig. 3c We next tested the ability of statins, the miR cluster, and TCF7L2 to modulate glucose production 182 in mouse primary hepatocytes. Data in Fig. 4 show that gluconeogenesis was increased in cells 183 incubated with either atorvastatin, simvastatin, or pravastatin, compared to vehicle (Fig. 4a) ; in cells 184 overexpressing miR-183/96/182 (via adenoviral transduction), compared to empty vector (Fig. 4b) ; and in 185 cells where Tcf7l2 was silenced using siRNA, compared to control oligonucleotides (Fig. 4c ). Consistent 186 with these data from cultured hepatocytes, the amounts of the key gluconeogenic enzymes 187 phosphoenolpyruvate kinase 1 (PCK1) and glucose-6-phosphatase, catalytic subunit (G6PC) increased 188 in the livers dosed with atorvastatin, compared to saline, and were inversely correlated to those of 189 TCF7L2 (Fig. 4d ). Collectively, these data demonstrate that statins, the miR cluster, and TCF7L2 are 190 critical regulators of the gluconeogenic pathway in cultured hepatocytes. 191 To test the functional consequences of miR-183/96/182 overexpression on hepatic glucose 192 production in vivo, we transduced mice with empty adenovirus or adenovirus encoding the miR cluster. 193 After 10 days, animals were fasted overnight and then injected i.p. with pyruvate early in the morning. 194 Hepatic gluconeogenic capacity was estimated from the conversion of pyruvate to glucose and its 195 release into circulation, which was monitored with a standard glucometer. Data in Fig. 5a and   196 Supplemental Data Fig. 4 show that, in two independent experiments, mice overexpressing the miR 197 cluster were able to sustain increased glycemia in response to the pyruvate challenge, compared to 198 control animals. These data demonstrate increased gluconeogenic capacity in the former mice. Animals 199 were allowed to recover after the pyruvate test for 48 h, and then some were fasted overnight, and some 200 allowed access to food. In agreement with the pyruvate challenge results, both mRNA ( Fig. 5b and   201 Supplemental Data Fig. 4b ) and protein (Fig. 5c ) panels show that miR overexpression in the liver 202 resulted in the decrease of TCF7L2 and the concomitant increase in PCK1 and G6PC. These results are 203 consistent with the previously reported suppressive effect of TCF7L2 on the gluconeogenic pathway via 204 negative regulation of PCK1 and G6PC expression (see discussion below). Interestingly, these changes 205 were much more apparent in the livers of fed mice, and indeed PCK1 and G6PC proteins were as 206 robustly expressed (if not more) in the livers of fed miR-overexpressing mice as in fasted control livers 207 11 (Fig. 5c ). This latter observation suggests that the miR-183/96/182-TCF7L2 pathway can overcome the 208 canonical nutritional regulation of these gluconeogenic genes. 209 Finally, we tested whether therapeutic silencing of each miR (or of all three) could revert the 210 atorvastatin-induced increase in hepatic gluconeogenesis. Mice were randomized for daily gavage with 211 saline or atorvastatin during 6 weeks, and then kept on treatment while dosed with one or more anti-miR 212 oligonucleotides on days 1, 2, 3, 9 and 12 (see Methods for details). Data in Fig. 5d show that the statin 213 (or statin plus scrambled anti-miR), raised the expression of all three miRNAs in liver, and that the anti-214 miRs were specific in silencing the expression of each cognate miR. Interestingly, silencing miR-96 215 modestly reduced the expression of miR-183, and vice-versa. This is consistent with reports in other 216 multi-cistronic miRNAs where altering the expression of one miR affects the levels of the others in the 217 cluster. Nonetheless, Tcf7l2 mRNA ( Fig. 5d ) and protein (Fig. 5e ) levels were efficiently reduced in the 218 livers of mice dosed with the statin, or statin plus scrambled anti-miR. Importantly, silencing miR-96 or 219 miR-183, but not miR-182, negated the statin-induced reduction in Tcf7l2 both at the mRNA (Fig. 5d ) and 220 protein (Fig. 5e ) level. Silencing all three miRNAs did not provide further increase in TCF7L2 abundance. 221 Supplemental Data Fig. 5a show that the expression of G6pc in the same livers largely opposed that of 222 Tcf7l2: both gluconeogenic transcripts were induced by the statin, and treatment with anti-miRs 223 abrogated the statin-dependent induction. Together, these data demonstrate that the miR-183/96/182 224 cluster is the in vivo mediator of the statin-induced regulation of hepatic TCF7L2 and gluconeogenic 225 enzymes. Interestingly, anti-miR182 was able to reduce the expression of G6pc (Supplemental Data Fig.   226 5a), despite having no effect on Tcf7l2 levels (Fig. 5c, d) . No miR-182 binding sites are predicted in 227 murine or human G6PC. Thus, the mechanism by which miR-182 modulates G6pc expression 228 independent of Tcf7l2 remains unknown. Supplemental Data Fig. 5a also shows results for the other 8 229 transcripts initially identified in this study: data demonstrate that the miR-183/96/182 cluster does indeed 230 control the liver expression of Sfxn5, Tmem189, Slc22a23, Nox4, and Mkl2; however, no changes in the 231 mRNA amounts of Pi3kr1, Pxmp4, and Bicd2 were noted. The reasons for the lack of response to 232 atorvastatin of these latter genes are unclear, since both transcripts clearly were regulated in other in 233 12 vivo ( Fig. 1 ) and in culture (Fig. 2d) experiments. It is possible that the nutritional status of the mice 234 (animals were not fasted in Fig. 5d-f and Supplemental Data Fig. 5 , as opposed to those in Figs. 1 and   235 2) may contribute additional regulatory mechanisms, beyond SREBP2, for these genes. Nonetheless, 236 Fig. 5f shows data from the same animals two days before sacrifice, when they were challenged with 237 pyruvate to measure in vivo gluconeogenesis. Consistent with the data in Fig. 5a The cardiovascular therapeutic benefits of statins are presumed to outweigh their diabetogenic effect. 248 Yet, it is critically important to establish the molecular mechanisms behind this undesired side effect. This 249 is especially important when considering preventive prescription to younger dyslipidemic patients who 250 will presumably be taking statins for several decades. Clinical and in vitro studies showed that statins 251 impair both pancreatic insulin secretion and peripheral insulin sensitivity (4, 5). Ours is the first report 252 demonstrating a direct effect of statins on hepatic glucose production. We show that the SREBP2-miR-253 183/96/182-TCF7L2 axis controls the expression of gluconeogenic enzymes, and increases glucose 254 production both in cultured hepatocytes and in mice (Fig. 6 ). Additionally, we show that therapeutic 255 silencing of the miR cluster normalizes Tcf7l2 expression and reverts statin-stimulated hepatic glucose 256 production. TCF7L2 is a member of the Wnt signaling pathway (33), and modulates the transcription of 257 target genes by interacting not only with b-catenin (its canonical partner), but also with the key metabolic 
